Research Questions and Future Directions

Key unanswered questions in ME/CFS pathophysiology:

1. What is the temporal sequence of system failures? Do metabolic, immune, and autonomic abnormalities appear simultaneously or sequentially?
2. Which vicious cycles are primary drivers vs. secondary consequences?
3. How do pathophysiological mechanisms differ between severity levels and disease subtypes?
4. What biomarkers predict treatment response to specific interventions?
5. Can early intervention prevent transition from acute to chronic ME/CFS?

These questions frame research priorities for the coming decade.

1 Achievement: Seven-Biomarker Systems Panel

The identification of a seven-biomarker panel (AMP, cDC1, LYVE1, IGHG2, FN1, VWF, THBS1) that achieves 91% diagnostic accuracy represents a major achievement in ME/CFS research. This panel demonstrates that ME/CFS is a multi-system disease with coordinated abnormalities across metabolic, immune, and vascular domains.

Significance: This biomarker panel provides first objective diagnostic test with high specificity, enabling earlier diagnosis and treatment initiation. The multi-system nature of the panel validates integrative models developed in this chapter and suggests that effective treatments will need to address multiple systems simultaneously.